Abstract
The insulin and insulin-like growth factor (IGF) family of proteins are part of a complex network that regulates cell proliferation and survival. While this system is undoubtedly important in prenatal development and postnatal cell growth, members of this family have been implicated in several different cancer types. Increased circulating insulin and IGF ligands have been linked to increased risk of cancer incidence. This observation has led to targeting the IGF system as a therapeutic strategy in a number of cancers. This chapter aims to describe the well-characterized biology of the IGF1R system, outline the rationale for targeting this system in cancer, summarize the clinical data as it stands, and discuss where we can go from here.
| Original language | English (US) |
|---|---|
| Title of host publication | Receptor Tyrosine Kinases |
| Editors | Rakesh Kumar, Paul B. Fisher |
| Publisher | Academic Press Inc. |
| Pages | 229-257 |
| Number of pages | 29 |
| ISBN (Print) | 9780128201428 |
| DOIs | |
| State | Published - 2020 |
Publication series
| Name | Advances in cancer research |
|---|---|
| ISSN (Print) | 0065-230X |
Bibliographical note
Funding Information:This work was supported by grants from the NIH T32 CA009138 (L.M.F.), 5P30 CA077598 (D.Y.) and P50 CA116201 (D.Y.).
Publisher Copyright:
© 2020 Elsevier Inc.
Keywords
- Cancer
- IGF
- IGFBP
- Insulin receptor
- Insulin-like growth factor receptor
- Animals
- Signal Transduction
- Receptor, IGF Type 1/antagonists & inhibitors
- Humans
- Insulin-Like Growth Factor I/antagonists & inhibitors
- Neoplasms/drug therapy
- Molecular Targeted Therapy
PubMed: MeSH publication types
- Review
- Journal Article
- Research Support, N.I.H., Extramural
